43
Participants
Start Date
August 31, 2006
Primary Completion Date
June 30, 2010
Study Completion Date
June 30, 2010
PF-3512676 + Erlotinib
"PF-3512676 0.2 mg/kg subcutaneously on days 1, 8 and 15 of each 21 day cycle until disease progression or unacceptable toxicity.~Erlotinib 150 mg orally daily (21 day cycles) until disease progression or unacceptable toxicity"
Erlotinib
Erlotinib 150 mg orally daily (21 day cycles) until disease progression or unacceptable toxicity
Pfizer Investigational Site, New York
Pfizer Investigational Site, Stony Brook
Pfizer Investigational Site, Philadelphia
Pfizer Investigational Site, Philadephia
Pfizer Investigational Site, Melbourne
Pfizer Investigational Site, Miami
Pfizer Investigational Site, Deerfield Beach
Pfizer Investigational Site, Huntsville
Pfizer Investigational Site, Daphne
Pfizer Investigational Site, Mobile
Pfizer Investigational Site, Kingsport
Pfizer Investigational Site, Louisville
Pfizer Investigational Site, Crestview Hills
Pfizer Investigational Site, Fairfield
Pfizer Investigational Site, Cincinnati
Pfizer Investigational Site, Cincinnati
Pfizer Investigational Site, Munster
Pfizer Investigational Site, Mason City
Pfizer Investigational Site, Chesterfield
Pfizer Investigational Site, Bridgeton
Pfizer Investigational Site, Kirkwood
Pfizer Investigational Site, Dallas
Pfizer Investigational Site, Dallas
Pfizer Investigational Site, Dalls
Pfizer Investigational Site, Pasadena
Pfizer Investigational Site, Rancho Cucamonga
Pfizer Investigational Site, Glendora
Pfizer Investigational Site, Pomona
Pfizer Investigational Site, West Covina
Pfizer Investigational Site, Corona
Pfizer Investigational Site, San Mateo
Pfizer Investigational Site, Greenbrae
Pfizer Investigational Site, Norwalk
Pfizer Investigational Site, Somerville
Pfizer Investigational Site, Hershey
Lead Sponsor
Pfizer
INDUSTRY